- Home
- IAE vs PMVP Comparison
IAE vs PMVP Comparison
Compare IAE & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IAE
Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | IAE | PMVP |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 76.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IAE | PMVP |
|---|---|---|
| Price | $8.39 | $1.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.5K | ★ 384.7K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.40 | $0.83 |
| 52 Week High | $8.34 | $1.88 |
Technical Indicators
Market Signals| Indicator | IAE | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 50.61 |
| Support Level | $7.08 | $1.37 |
| Resistance Level | N/A | $1.50 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 98.30 | 28.12 |
Price Performance
Historical ComparisonAbout IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.